AgeneBio Obtains National Institute on Aging Grant for Phase 3 Trial of Its Alzheimer’s Therapy AGB101

AgeneBio Obtains National Institute on Aging Grant for Phase 3 Trial of Its Alzheimer’s Therapy AGB101
AgeneBio has obtained a National Institute on Aging grant to conduct a Phase 3 clinical trial of AGB101 (levetiracetam), a compound intended to prevent people with mild memory impairment from developing Alzheimer’s disease. The agency, part of the National Institutes of Health (NIH), has been backing the potential therapy’s development for some time. AgeneBio did not announce the size

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *